Bharat Parenterals Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BPLPHARMA.BO | THEMISMED.BO | BDH.BO | BAJAJHCARE.NS | AAREYDRUGS.NS | WINDLAS.NS | |
|---|---|---|---|---|---|---|
| Market cap | 12.56B | 9.36B | 2.45B | 10.77B | 3.49B | 19.01B |
| P/E (TTM) | — | 23.5 | 21.0 | 43.8 | 74.4 | 29.5 |
| Forward P/E | — | — | 59.2 | — | — | — |
| Price/book | 3.0 | 2.4 | 3.2 | 1.9 | 2.1 | 3.3 |
| Dividend yield | 0.06% | 0.50% | 1.17% | 0.49% | — | 0.72% |
| 1-year change | +50.11% | −15.42% | −1.43% | −30.88% | +10.12% | −5.35% |
| Today | +1.16% | +1.22% | −0.20% | +3.71% | +0.08% | +5.47% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All BPLPHARMA.BO news ›Bharat Parenterals Q2 FY27 Call: Key Dates, Metrics
Welcome to Multibagg AI Log in to access personalized features Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and…
Bharat Parenterals returns to profit as Innoxel leads EBITDA
Welcome to Multibagg AI Log in to access personalized features Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and…
Bharat Parenterals Returns to Profit as Q2 Revenue Rises 111%
Welcome to Multibagg AI Log in to access personalized features Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and…
Bharat Parenterals shines as its arm commences commercial supply to United States
Mumbai, October 22 (Udaipur Kiran): Bharat Parenterals is currently trading at Rs. 1805.30, up by 75.00 points or 4.33% from its previous closing of Rs. 1730.30 on the BSE. The scrip opened at Rs. 1775.40 and has touched a high and low of…
Bharat Parenterals Subsidiary Innoxel Starts U.S. Commercial Sales With October 20 Launch
Market snapshot: Bharat Parenterals Limited has announced that its 55.89% subsidiary, Innoxel Lifesciences, commenced commercial sales in the United States with its first product launch on October 20, 2026. This marks the transition of…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- multibagg.ai3
- sahi.com1
- udaipurkiran.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.